


# Depression...disturbed sleep...



## Sinequan<sup>\*</sup>

brand of doxepin \* Trade Mark

**lifts depression ...  
promotes restful sleep**

- SEDATIVE ANTIDEPRESSANT
- ONCE NIGHTLY DOSAGE

**Indications:** depression with or without anxiety. **Contraindications:** glaucoma, urinary retention, hypersensitivity to the drug. **Side effects:** dry mouth and drowsiness are most commonly reported. **Precautions:** Sinequan may potentiate other compounds - e.g. monoamine oxidase inhibitors; not recommended in pregnancy or children under 12 years age. **Dosage:** range 30 mg to 300 mg daily in divided doses, up to 100 mg may be given as a single dose at night. **Packs and Basic N.H.S. Cost:** 10 mg capsules (PL 57/5032), pack of 100, £2.98; 25 mg capsules (PL 57/5033), pack of 100, £4.24; 50 mg capsules (PL 57/5034) pack of 100, £7.01; 75 mg capsules (PL 57/0133), pack of 60, £6.64. Full information on request to the Company.

**Pfizer** PFIZER LIMITED  
SANDWICH, KENT

# Epilim<sup>®</sup>

sodium valproate

200 enteric-coated, 500 enteric-coated tablets; syrup.

Epilim is a powerful anticonvulsant capable of providing control for the majority of adults with tonic-clonic seizures or other epilepsies, including those not well controlled on previous treatments. Because it controls without sedation, Epilim allows many patients to lead full, normal lives.

#### Presentation

- 1 Epilim 200 enteric-coated. A lilac-coloured enteric-coated tablet containing 200mg sodium valproate
- 2 Epilim tablets. A white scored tablet containing 200mg sodium valproate
- 3 Epilim 500 enteric-coated. A lilac-coloured enteric-coated tablet containing 500mg sodium valproate
- 4 Epilim Syrup. A red cherry-flavoured syrup containing 200mg sodium valproate per 5ml

#### Indications

Epilepsy. In women of childbearing age, Epilim should be used only in severe cases or in those resistant to other treatment.

#### Dosage and Administration

To be taken with or after food, enteric-coated and plain tablets should be swallowed whole. Optimum dosage should be established using the 200mg enteric-coated tablet. Epilim 500 enteric-coated is recommended for patients requiring high dosages.

**Adults:** Dosage should start at 600mg/day, in divided doses, increasing by 200mg/day at three-day intervals until control is achieved. (Maximum Dose 2600mg/day)

In patients already receiving other therapy the same pattern should be followed.

Dosage of barbiturates should be reduced as that of Epilim is increased. The respective dosages should be adjusted, during the stabilisation period, to give optimum control at the lowest possible combined-dose level, and it may be found possible to maintain control with Epilim alone.

Once known enzyme-inducers have been withdrawn, it may be possible to maintain seizure control on a reduced dose of Epilim. Although a method of measuring plasma levels is available, optimum dosage must ultimately be determined by seizure-control.

**Children over 20kg:** Initially 400mg/day in divided doses with spaced increases until control is achieved (usually in the range of 20-30mg/kg/day).

**Children under 20kg:** 20mg/kg of body weight per day, in severe cases, this may be increased up to 50mg/kg/day but should be undertaken only in patients in whom plasma valproate levels, clinical chemistry and haematological parameters can be monitored.

#### Contra-Indications, Warnings, etc.

Liver dysfunction, including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents occurred during the first six months of therapy, the period of maximum risk being 2-12 weeks. No deaths have occurred in patients receiving the drug continuously for more than 6 months.

Biochemical tests may not always become abnormal early in the evolution of hepatic failure; non-specific findings such as loss of seizure control, malaise, anorexia and vomiting, developing after a period of satisfactory Epilim treatment may alert the clinician to the possibility of hepatic damage.

Epilim should not be administered to patients with pre-existing hepatic dysfunction.

All patients for whom treatment with Epilim is contemplated should have the liver function assessed (including serum fibrinogen and albumin levels) prior to commencement of therapy. Liver function should be carefully monitored, particularly during the first six months of therapy, and when dosage is being titrated upwards. Patients with a prior history of liver disease or with severe or unusual seizure disorders, e.g. those accompanied by mental retardation and/or organic brain disease should be followed particularly carefully. Transient elevations of liver enzymes are not uncommon during early treatment with Epilim, but, if elevations are accompanied by other evidence of hepatic dysfunction, especially raised serum bilirubin or lowered serum fibrinogen, then the drug should be immediately withdrawn.

Hyperammonaemia without hepatic damage can occur in patients during treatment with valproic acid or sodium valproate. This may manifest clinically as vomiting, ataxia and increasing clouding of consciousness. Should these symptoms occur Epilim should be discontinued.

Valproic acid inhibits second stage of platelet aggregation. Reversible prolongation of bleeding time and thrombocytopenia have been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication pending investigations. Patients receiving Epilim should be monitored for platelet function before major surgery. Red cell hypoplasia and leucopenia have been reported. The blood picture returned to normal when the drug was discontinued. Pancreatitis has occurred in patients receiving valproic acid or sodium valproate. Patients experiencing acute abdominal pain should have serum amylase estimated.

Minor gastric irritation and, less frequently, nausea may occur at the start of treatment but these problems can usually be overcome by administering Epilim tablets or syrup with or after food, or by transferring the patient to the Epilim enteric-coated formulations. Transient hair loss has been noted in some patients. Regrowth normally begins within six months. Tremor has occasionally been observed at high dosage. Oedema has been reported. Increase in alertness, appetite and weight may occur.

**Combined medication:** Epilim is generally well tolerated in combination with other anti-epileptic agents; however, as interaction occurs between these compounds, it may sometimes be necessary to reduce the dosage of other drugs when adding Epilim to existing anti-convulsant therapy. Epilim may also potentiate the effect of monoamine oxidase inhibitors and other anti-depressants, and dosage of such compounds should be reduced.

**Diabetic patients:** Epilim may give false positives in urine testing for ketones. Care should be taken when treating diabetic patients with Epilim Syrup which contains 3.6g sucrose per 5ml.

**Women of childbearing age:** Valproic acid or sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age, the benefits of these compounds should be weighed against the possible hazard suggested by these findings.

#### Further Information

When plasma valproic acid is within the recommended range of 50-120mg/litre (350-840m mol/litre) and serum albumin levels are normal, about 90% of the drug is bound to albumin. If the total plasma valproic acid rises above the upper range of normal, or if there is hypoalbuminaemia, the percentage of free valproic acid may rise markedly in proportion to any dosage increase and may be associated with a higher incidence of adverse effects.

#### Product Licence Numbers, Names and Addresses

Epilim 200 enteric-coated tablets 0623 0006

Epilim Tablets 0623/0001

Epilim 500 enteric-coated tablets 0623 0005

Epilim Syrup 0623/0004

#### NHS Cost

Epilim 200 enteric-coated tablets 100 £7.04

Epilim 500 enteric-coated tablets 100 £17.60

Epilim Syrup 200ml £4.03

Epilim 200mg tablets 100 £5.45

#### LABAZ: Sanofi UK Ltd

Regent House, Heaton Lane,

Stockport SK4 1AG, Cheshire

Telephone: 061-480 0895/6/7/8

Additional Information is available from the Company.



Additional information is available from **LABAZ: Sanofi U.K. Ltd**, Regent House Heaton Lane Stockport SK4 1AG

For many grand mal patients



a full, normal life under the protection of

**Epilim**  
sodium valproate

200 enteric-coated, 500 enteric-coated tablets; syrup.

#### Presentation

Madopar contains a combination of levodopa and the decarboxylase inhibitor benserazide in the ratio of 4:1. Madopar 62.5 capsules containing 50mg levodopa and 12.5mg benserazide hydrochloride (equivalent to 12.5mg of the base). Madopar 125 capsules containing 100mg levodopa and 25mg benserazide hydrochloride (equivalent to 25mg of the base). Madopar 250 capsules containing 200mg levodopa and 50mg benserazide hydrochloride (equivalent to 50mg of the base).

#### Indications

Parkinsonism: idiopathic, post-encephalitic.

#### Dosage

Dosage is variable and the patient should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 62.5 (two to four capsules of Madopar 250) daily in divided doses, most patients requiring no more than six capsules of Madopar 125 daily in some elderly patients initial treatment with one capsule of Madopar 62.5 once or twice daily increasing by one capsule every third or fourth day may suffice.

Patients who experience fluctuations in response may also benefit from administration of smaller more frequent doses using Madopar 62.5.

#### Contra-indications

Narrow-angle glaucoma, severe psychoneuroses or psychoses. It should not be given in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal, to patients under 25 years of age, to pregnant women, or to patients who have a history of, or who may be suffering from, a malignant melanoma.

#### Precautions

Drugs which interfere with central amine mechanisms should be avoided. Endocrine, renal, pulmonary or cardiovascular disease, hepatic disorder, peptic ulcer, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as rapid mobilisation may increase the risk of injury.

#### Side-effects

Nausea and vomiting; cardiovascular disturbances; psychiatric disturbances; involuntary movements.

#### Packings

Madopar 62.5 capsules, Madopar 125 capsules and Madopar 250 capsules in packings of 100.

#### Licence Numbers


0031/0125 (Madopar 62.5 capsules), 0031/0073 (Madopar 125 capsules), 0031/0074 (Madopar 250 capsules).

#### Basic NHS Cost

Madopar capsules 62.5  
£3.49 per 100  
Madopar capsules 125  
£6.29 per 100  
Madopar capsules 250  
£11.25 per 100

# 4+1

*the  
right balance  
in Parkinson's  
disease*



# Madopar

levodopa plus benserazide

*the original 4+1 combination  
in three dosage forms 62.5 125 and 250*



Roche Products Limited  
PO Box 8  
Welwyn Garden City  
Hertfordshire AL7 5AY  
Madopar is a trade mark.  
JSC2168/581.

## A NEW CONCEPT IN E.C.T.

THREE NEW CONSTANT CURRENT E.C.T. APPARATUS NOW  
SUPPLEMENT OUR WIDELY USED RANGE OF Mk. 4 MODELS

*Also*

**SOMLEC**  
ELECTRO SLEEP APPARATUS


*Send for full details*

**ELECTRON LTD.**

KNAP CLOSE, LETCHWORTH, HERTS. SG6 1AQ  
ENGLAND

Telephone LETCHWORTH 2124 Cables ELECTRON LETCHWORTH

TELEX 825562 CHACOM ECTRON



**A new practical manual  
for surgeons**

## Manual of Spinal Surgery

D H R Jenkins, R D Weeks,  
A C M C Yau and R R Du

*Order today from your  
bookseller. Further  
information and leaflet  
available from*



**Butterworths**

Borough Green, Sevenoaks,  
Kent TN15 8PH


Two orthopaedic surgeons and a neurosurgeon have teamed up to write this practical manual of spinal surgery. Almost all commonly used operations are discussed and critically evaluated, but they concentrate on those which have proved reliable and successful.

This is a book of techniques and so particular emphasis has been placed on the illustrations. The principal stages of all the operations described in the text are illustrated with pictures drawn by Dr Romeo Du, himself an orthopaedic surgeon.

Designed as a working manual, this book will find a place both on the library shelf, and in the operating theatre. It will be a frequent and easily used source of advice for all those faced with the management of a specific spinal problem.

**September 1981 120 pages £15.00**

# The New MS8. Allows you more time to be a doctor



Compact, mobile, fast and easy to use, the MS8 represents a major step forward in the design of EEG machines. The MS8 is compact, mobile, fast and easy to use, with the aid of the latest technology.

MS8 has been created, potentially with advanced micro-electronic hardware, and a flexible display and recording system.

- 4 channels • 4 channels • 4 channels
- 12 channels • 12 channels • 12 channels
- 12 channels • 12 channels • 12 channels
- 12 channels • 12 channels • 12 channels


MS8 is available in a range of configurations to suit your needs. It is a compact, mobile, fast and easy to use machine, with the aid of the latest technology.

**medelec**  
A Vickers Medical Company



Medelec is a leader in the design and manufacture of EEG machines. The MS8 is a compact, mobile, fast and easy to use machine, with the aid of the latest technology.

Medelec - The Leaders in EEG



## Disipal has made her a little more responsive to her phenothiazine therapy.

The addition of Disipal to phenothiazine therapy enables optimum therapeutic response to a fixed dose of phenothiazine to be achieved. Disipal elevates the patient's mood, thus allowing the depression so often associated with major tranquilizer therapy.

### Drug of choice

In a study of 100 patients with depression, the authors concluded that, in combination with phenothiazine, Disipal controls extra-pyramidal reactions and depression.<sup>1</sup>

### Increased response

Patients with a clinical response to a fixed dose of phenothiazine in the treatment of a patient whose response to phenothiazine is inadequate will respond to the combination therapy.

**For patients on major tranquilizer therapy**

## Disipal

- \* controls extra-pyramidal reactions
- \* elevates patient mood.

<sup>1</sup> Journal of Clinical Pharmacy and Therapeutics, 1977, 2, 137-141.

Disipal is a registered trademark of Sandoz.

© 1981 Sandoz Pharmaceuticals Limited, UK.

Disipal is available in 100mg and 200mg tablets.

# JOURNAL OF MENTAL DEFICIENCY RESEARCH

*Editor:* Dr B W Richards

THE JOURNAL OF MENTAL DEFICIENCY RESEARCH  
contains original research on medical and psychological problems  
relevant to mental subnormality.

**Recent articles include:**

*The Effect of Treatment on Mental and Psychomotor Development of  
Marasmic Infants according to Age of Admission.* J. M. Celedon,  
Diane Cszasz, Jennifer Middleton and Isidora de Andraca.

*Age and Mortality Trends in Residents of an Institute for the Mentally  
Handicapped.* B. W. Richards and A. Q. Siddiqui.

*Preferences in Attention to Visual Cues in Down Syndrome and Normal  
Children.* B. Stratford.

*Dental Asymmetry and Mental Retardation: A Comparison of Subjects  
with Mental Retardation Resulting from Prenatal or Postnatal  
Influences.* H. S. Barden

*Follow-up of Case of Advanced Survival and Trisomy 18.* Arabella  
Smith and Gesina M. den Dulk.

*A New Approach to the Treatment of Phenylketonuria.* O. E. Pratt.

*Extra Dicentric 15pter → q21|22 Chromosomes in Five Unrelated  
Patients with a Distinct Syndrome of Progressive Psychomotor  
Retardation, Seizures, Hyper-reactivity and Dermatoglyphic Abnor-  
malities.* Maria Zannotti, A. Preto, Paola Rossi Giorvanardi  
and B. Dallapiccola.

Published quarterly by

**THE NATIONAL SOCIETY  
FOR  
MENTALLY HANDICAPPED CHILDREN AND ADULTS**

**123 Golden Lane, London EC1Y 0RT**

**Yearly Subscription £20.00**

**U.S.A. \$60.00**